Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745032 | 1.00 | GAA (0.73) | GAAMAPTKDM4EPTK2BMAPK1 | |
| Ammonia Solution, Strong SCHEMBL14746306 | 0.98 | GAA (0.71) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL3935104 | 0.93 | MAPT (0.65) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL30565926 | 0.93 | MAPT (0.65) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL29666122 | 0.87 | MAPT (0.57) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL31173630 | 0.85 | MAPT (0.60) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL20475482 | 0.85 | MAPT (0.60) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL30900439 | 0.85 | GAA (0.64) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL6151809 | 0.85 | GAA (0.69) | GAAMAPTKDM4EPTK2BMAPK1 | |
| SCHEMBL519972 | 0.85 | GAA (0.69) | GAAMAPTKDM4EPTK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288387-B2 | Napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-10-16 | — | — | US | claimed |
| US-20110166346-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2011-07-07 | — | — | US | claimed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | claimed |
| WO-2009110000-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | claimed |
| EP-2044938-A2 | Radioprotectors | Peter MacCallum Cancer Institute (AU) | 2009-04-08 | — | — | EP | claimed |
| JP-4125369-B2 | — | — | 2008-07-30 | — | — | JP | claimed |
| EP-0857067-A4 | RADIOPROTECTORS | PETER MACCALLUM CANCER INST (AU) | 2005-01-19 | — | — | EP | claimed |
| JP-2000501697-A | — | — | 2000-02-15 | — | — | JP | claimed |
| EP-0857067-A1 | RADIOPROTECTORS | The Inner and Eastern Health Care Network (AU) | 1998-08-12 | — | — | EP | claimed |
| WO-1997004776-A1 | RADIOPROTECTORS | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 1997-02-13 | — | — | WO | claimed |
| WO-2024220556-A2 | HETEROCYCLIC SUMO1 SMALL MOLECULE DEGRADERS AND USE THEREOF | HB THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-118344358-A | HPK1 inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024129780-A1 | BENZIMIDAZOLE DERIVATIVES AS GPX4 INHIBITORS | SONATA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129780-A1 | BENZIMIDAZOLE DERIVATIVES AS GPX4 INHIBITORS | SONATA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-117886798-A | Substituted benzimidazoles and use thereof | 河南中医药大学 | 2024-04-16 | — | — | CN | disclosed |
| WO-2001053268-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-0857067-A1 | RADIOPROTECTORS | The Inner and Eastern Health Care Network (AU) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997004776-A1 | RADIOPROTECTORS | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166346-A1 | NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NAP1L4, NAP1L1, CCNI | GAA 3313/4885MAPT 3299/4885KDM4E 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.